30,936 results match your criteria chronic myeloid


Asciminib for the treatment of patients with chronic myeloid leukemia.

Authors:
Jorge Cortes

Clin Adv Hematol Oncol 2021 Apr;19(4):207-208

Georgia Cancer Center, Augusta, Georgia.

View Article and Full-Text PDF

CAR T-Cell Therapy in Hematologic Malignancies: Clinical Role, Toxicity, and Unanswered Questions.

Am Soc Clin Oncol Educ Book 2021 Mar;41:1-20

Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.

At the time of writing, five anti-CD19 CAR T-cell products are approved by the U.S. Food and Drug Administration for seven different indications in lymphoid malignancies, including B-cell non-Hodgkin lymphoma, pediatric B-cell acute lymphoblastic leukemia, and multiple myeloma. Read More

View Article and Full-Text PDF

Relevance of treatment-free remission recommendations in chronic phase chronic leukemia patients treated with frontline tyrosine kinase inhibitors.

Cancer Med 2021 May 14. Epub 2021 May 14.

Groupe France Intergroupe des Leucémies Myéloïdes Chroniques, Hôpital Haut-Lévêque, Pessac, France.

Background: Tyrosine kinase inhibitors (TKI) can be safely discontinued in chronic phase chronic myeloid leukemia (CP-CML) patients who had achieved a sustained deep molecular response. Based on the results of discontinuation trials, recommendations regarding patient selection for a treatment-free remission (TFR) attempt had been proposed. The aims of this study were to evaluate the rate of patients eligible for TKI discontinuation and molecular recurrence-free survival (MRFS) after stop according to recommendations. Read More

View Article and Full-Text PDF

Whole-exome sequencing identifies somatic mutations associated with lung cancer metastasis to the brain.

Ann Transl Med 2021 Apr;9(8):694

Department of Neurosurgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.

Background: Lung cancer is the most aggressive cancer, resulting in one-quarter of all cancer-related deaths, and its metastatic spread accounts for >70% of these deaths, especially metastasis to the brain. Metastasis-associated mutations are important biomarkers for metastasis prediction and outcome improvement.

Methods: In this study, we applied whole-exome sequencing (WES) to identify potential metastasis-related mutations in 12 paired lung cancer and brain metastasis samples. Read More

View Article and Full-Text PDF

SIGLEC1 (CD169): a marker of active neuroinflammation in the brain but not in the blood of multiple sclerosis patients.

Sci Rep 2021 May 13;11(1):10299. Epub 2021 May 13.

Department of Neuropathology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.

We aimed to evaluate SIGLEC1 (CD169) as a biomarker in multiple sclerosis (MS) and Neuromyelitis optica spectrum disorder (NMOSD) and to evaluate the presence of SIGLEC1 myeloid cells in demyelinating diseases. We performed flow cytometry-based measurements of SIGLEC1 expression on monocytes in 86 MS patients, 41 NMOSD patients and 31 healthy controls. Additionally, we histologically evaluated the presence of SIGLEC1 myeloid cells in acute and chronic MS brain lesions as well as other neurological diseases. Read More

View Article and Full-Text PDF

In vitro performance of free and encapsulated bromelain.

Sci Rep 2021 May 13;11(1):10195. Epub 2021 May 13.

Faculty of Pharmaceutical Sciences, University of Campinas (UNICAMP), Candido Portinari Street, 200, Cidade Universitária ″Zeferino Vaz″, Campinas, 13083-871, SP, Brazil.

For centuries, bromelain has been used to treat a range of ailments, even though its mechanism of action is not fully understood. Its therapeutic benefits include enzymatic debridement of the necrotic tissues of ulcers and burn wounds, besides anti-inflammatory, anti-tumor, and antioxidant properties. However, the protease is unstable and susceptible to self-hydrolysis over time. Read More

View Article and Full-Text PDF

Ex vivo expansion of dysfunctional regulatory T lymphocytes restores suppressive function in Parkinson's disease.

NPJ Parkinsons Dis 2021 May 13;7(1):41. Epub 2021 May 13.

Department of Neurology, Houston Methodist Neurological Institute, Houston Methodist Research Institute, Houston Methodist Hospital, Houston, TX, USA.

Inflammation is a pathological hallmark of Parkinson's disease (PD). Chronic pro-inflammatory responses contribute to the loss of neurons in the neurodegenerative process. The present study was undertaken to define the peripheral innate and adaptive immune contributions to inflammation in patients with PD. Read More

View Article and Full-Text PDF

Common clonal origin of chronic myelomonocytic leukemia and B cell acute lymphoblastic leukemia in a patient with a germline variant.

Cold Spring Harb Mol Case Stud 2021 May 13. Epub 2021 May 13.

McGill University.

Hematological malignancies are broadly divided into myeloid and lymphoid neoplasms, reflecting the two major cellular lineages of the hematopoietic system. It is generally rare for hematological malignancies to spontaneously progress with a switch from myeloid to lymphoid lineage. We describe the exceptional case of a patient who sequentially developed myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), and B cell acute lymphoblastic leukemia (B-ALL), as well as our investigation into the underlying pathogenesis. Read More

View Article and Full-Text PDF

[Impact of hyperleucocytosis on erythrocytic parameters of cell blood count: management by Sysmex XN-10 RET analyzer].

Ann Biol Clin (Paris) 2021 Apr;79(2):181-189

Laboratoire d'hématologie, Établissement français du sang de Bourgogne Franche-Comté, Besançon.

Introduction: Extreme hyperleukocytosis can interfere with the haemoglobin measurement, red blood cell counts and the calculation of the erythrocyte indices. Current recommendations require various sample manipulations, resulting in high inter-operator variability. The aim of our study was to define an automated method on the XN-10 RET analyser to ensure the speed and accuracy of the haemogram results reported in cases of extreme hyperleukocytosis. Read More

View Article and Full-Text PDF

The diverse roles of myeloid derived suppressor cells in mucosal immunity.

Cell Immunol 2021 Apr 9;365:104361. Epub 2021 Apr 9.

The Concern Foundation Laboratories at The Lautenberg Center for Immunology and Cancer Research, Israel-Canada Medical Research Institute, Faculty of Medicine, The Hebrew University, Jerusalem, Israel. Electronic address:

The mucosal immune system plays a vital role in protecting the host from the external environment. Its major challenge is to balance immune responses against harmful and harmless agents and serve as a 'homeostatic gate keeper'. Myeloid derived suppressor cells (MDSCs) are a heterogeneous population of undifferentiated cells that are characterized by an immunoregulatory and immunosuppressive phenotype. Read More

View Article and Full-Text PDF

AKR1C3 decreased CML sensitivity to Imatinib in bone marrow microenvironment via dysregulation of miR-379-5p.

Cell Signal 2021 May 10:110038. Epub 2021 May 10.

Department of Physiology, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 211198, Jiangsu, China. Electronic address:

Background: Drug resistance is an important cause of death for most patients with chronic myeloid leukemia (CML). The bone marrow microenvironment is believed to be mainly responsible for resistance to BCR-ABL tyrosine kinase inhibitors. The mechanism involved, however, is still unclear. Read More

View Article and Full-Text PDF

Myeloid ATP Citrate Lyase Regulates Macrophage Inflammatory Responses Without Altering Inflammatory Disease Outcomes.

Front Immunol 2021 26;12:669920. Epub 2021 Apr 26.

Department of Molecular Cell Biology and Immunology, Amsterdam Cardiovascular Sciences, Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.

Macrophages are highly plastic, key regulators of inflammation. Deregulation of macrophage activation can lead to excessive inflammation as seen in inflammatory disorders like atherosclerosis, obesity, multiple sclerosis and sepsis. Targeting intracellular metabolism is considered as an approach to reshape deranged macrophage activation and to dampen the progression of inflammatory disorders. Read More

View Article and Full-Text PDF

Long-term treatment-free remission in patients with chronic myeloid leukemia after second-line nilotinib: ENESTop 5-year update.

Leukemia 2021 May 12. Epub 2021 May 12.

Cancer Center of Bordeaux, Institut Bergonié, INSERM U1218, University of Bordeaux, Bordeaux, France.

The ENESTop study evaluated treatment-free remission (TFR) in patients with chronic myeloid leukemia (CML) in chronic phase who had received ≥3 years of tyrosine kinase inhibitor therapy and achieved sustained deep molecular response only after switching from imatinib to nilotinib. After 1-year nilotinib consolidation, 126 patients attempted TFR. At 48 weeks (primary analysis), 57. Read More

View Article and Full-Text PDF

MDSC: Markers, development, states, and unaddressed complexity.

Immunity 2021 May;54(5):875-884

The Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Human Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address:

Myeloid-derived suppressor cells (MDSCs) are one of the most discussed biological entities in immunology. While the context and classification of this group of cells has evolved, MDSCs most commonly describe cells arising during chronic inflammation, especially late-stage cancers, and are defined by their T cell immunosuppressive functions. This MDSC concept has helped explain myeloid phenomena associated with disease outcome, but currently lacks clear definitions and a unifying framework across pathologies. Read More

View Article and Full-Text PDF

Chronic intestinal inflammation drives colorectal tumor formation triggered by dietary heme iron in vivo.

Arch Toxicol 2021 May 12. Epub 2021 May 12.

Institute of Toxicology, University Medical Center Mainz, 55131, Mainz, Germany.

The consumption of red meat is associated with an increased risk for colorectal cancer (CRC). Multiple lines of evidence suggest that heme iron as abundant constituent of red meat is responsible for its carcinogenic potential. However, the underlying mechanisms are not fully understood and particularly the role of intestinal inflammation has not been investigated. Read More

View Article and Full-Text PDF

Sirtuin1 and Chronic Myeloid Leukemia: a Comprehensive Glance at Drug Resistance.

Clin Lab 2021 May;67(5)

Background: Chronic myeloid leukemia (CML) is a myeloproliferative disorder, which is caused by BCR-ABL fusion that has tyrosine kinase activity. The emergence of the first generation of tyrosine kinase inhibitors increased survival in patients. CML patients remain in silent phase for a long time by using drugs such as imatinib. Read More

View Article and Full-Text PDF

Recent advances in understanding chronic myeloid leukemia: where do we stand?

Fac Rev 2021 1;10:35. Epub 2021 Apr 1.

Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, 60596 Frankfurt, Germany.

While the need for complete eradication of leukemic stem cells (LSCs) in chronic myeloid leukemia may be controversial, it is agreed that remaining LSCs are the cause of relapse and disease progression. Current efforts are focused on the understanding of the persistence of immunophenotypically defined LSCs, which feature abnormalities in signaling pathways relating to autophagy, metabolism, epigenetics, and others and are influenced by leukemia cell-extrinsic factors such as the immune and bone marrow microenvironments. In sum, these elements modulate response and resistance to therapies and the clinical condition of treatment-free remission (TFR), the newly established goal in CML treatment, once the patient has achieved a durable molecular remission after treatment with tyrosine kinase inhibitors. Read More

View Article and Full-Text PDF

Dasatinib-induced chylothorax in a patient with chronic myeloid leukaemia: a case report and literature review.

Respirol Case Rep 2021 Jun 7;9(6):e00753. Epub 2021 May 7.

Department of Internal Medicine Kaohsiung Medical University Hospital, Kaohsiung Medical University Kaohsiung Taiwan.

Dasatinib is a potent and effective second-generation oral tyrosine kinase inhibitor that is clinically indicated for the treatment of imatinib-resistant or imatinib-intolerant breakpoint cluster region-Abelson (BCR-ABL)-positive chronic myeloid leukaemia (CML) or for Philadelphia chromosome-positive acute lymphocytic leukaemia. The most common adverse events associated with dasatinib therapy are skin rash, gastrointestinal upset, pancytopenia, pulmonary hypertension, and fluid retention, including pleural effusion. However, chylothorax secondary to dasatinib administration has rarely been reported. Read More

View Article and Full-Text PDF

Intracranial Hemorrhage in a Pediatric Patient with Chronic Myeloid Leukemia in Chronic Phase: A Case Report.

Case Rep Oncol 2021 Jan-Apr;14(1):525-530. Epub 2021 Mar 22.

Department of Pediatric Oncology, Fukushima Medical University, Fukushima, Japan.

Chronic myeloid leukemia (CML) is an uncommon entity in pediatric patients. CML in chronic phase (CML-CP) has a relatively favorable outcome. Leukostasis occurs in 9. Read More

View Article and Full-Text PDF

Clonal Upregulation of Effector Cytotoxic T Lymphocytes in a Patient with Multiple Tyrosine Kinase Inhibitor-Refractory Chronic Myeloid Leukemia with Long-Term Survival.

Case Rep Oncol 2021 Jan-Apr;14(1):493-499. Epub 2021 Mar 22.

Department of Hematology, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan.

We present the case of a patient with multiple tyrosine kinase inhibitor (TKI)-refractory chronic phase chronic myeloid leukemia (CP-CML) with a T315I mutation of . Dasatinib, a second-generation TKI, was administered as the initial treatment but achieved neither a cytogenetic nor molecular response. A mutational analysis of revealed that the patient had a T315I mutation. Read More

View Article and Full-Text PDF

Declining neutrophil production despite increasing G-CSF levels is associated with chronic inflammation in elderly rhesus macaques.

J Leukoc Biol 2021 May 11. Epub 2021 May 11.

Division of Immunology, Tulane National Primate Research Center, Tulane University, Covington, Louisiana, USA.

Aging is characterized by a loss of bone marrow hematopoietic tissue, systemic chronic inflammation, and higher susceptibility to infectious and noninfectious diseases. We previously reported the tightly regulated kinetics and massive daily production of neutrophils during homeostasis in adult rhesus macaques aged 3 to 19 yr (equivalent to approximately 10 to 70 yr of age in humans). In the current study, we observed an earlier release of recently dividing neutrophils from bone marrow and greater in-group variability of neutrophil kinetics based on in vivo BrdU labeling in a group of older rhesus macaques of 20-26 yr of age. Read More

View Article and Full-Text PDF

[Precision diagnostics and therapy in hematological malignancies].

Lakartidningen 2021 May 10;118. Epub 2021 May 10.

professor, överläkare, Karolinska institutet och Karolinska universitetssjukhuset.

Precision diagnostics and therapy have been implemented rather early in clinical hematology due to the easy accessibility of blood and bone marrow, allowing not only for consecutive genetic analysis at diagnosis, remission and relapse, but also for culturing these cells and testing new drugs in vitro. One contributing factor has also been the relatively low number of »driver« mutations in hematologic malignancies and that some of them are gain of function mutations that are relatively easy to target by drugs. Examples of this development are ABL1-, JAK2-, and FLT3-inhibitors for the treatment of chronic myeloid leukemia, myeloproliferative neoplasms, and acute myeloid leukemia, respectively. Read More

View Article and Full-Text PDF

LENZILUMAB EFFICACY AND SAFETY IN NEWLY HOSPITALIZED COVID-19 SUBJECTS: RESULTS FROM THE LIVE-AIR PHASE 3 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL.

medRxiv 2021 May 5. Epub 2021 May 5.

Background: Severe COVID-19 pneumonia results from a hyperinflammatory immune response (cytokine storm, CS), characterized by GM-CSF mediated activation and trafficking of myeloid cells, leading to elevation of downstream inflammatory chemokines (MCP-1, IL-8, IP-10), cytokines (IL-6, IL-1), and other markers of systemic inflammation (CRP, D-dimer, ferritin). CS leads to fever, hypotension, coagulopathy, respiratory failure, ARDS, and death. Lenzilumab is a novel Humaneered anti-human GM-CSF monoclonal antibody that directly binds GM-CSF and prevents signaling through its receptor. Read More

View Article and Full-Text PDF

Overcoming TKI resistance in a patient with chronic myeloid leukemia using combination BCR-ABL inhibition with asciminib and bosutinib.

Am J Hematol 2021 May 10. Epub 2021 May 10.

Winship Cancer Institute of Emory University, Bone Marrow and Stem Cell Transplant Center, Atlanta, GA.

View Article and Full-Text PDF

Kinetics of peripheral blood neutrophils in severe coronavirus disease 2019.

Clin Transl Immunology 2021 29;10(4):e1271. Epub 2021 Apr 29.

Laboratory of Molecular Immunology Department of Microbiology, Immunology and Transplantation Rega Institute, KU Leuven Leuven Belgium.

Objectives: Emerging evidence of dysregulation of the myeloid cell compartment urges investigations on neutrophil characteristics in coronavirus disease 2019 (COVID-19). We isolated neutrophils from the blood of COVID-19 patients receiving general ward care and from patients hospitalised at intensive care units (ICUs) to explore the kinetics of circulating neutrophils and factors important for neutrophil migration and activation.

Methods: Multicolour flow cytometry was exploited for the analysis of neutrophil differentiation and activation markers. Read More

View Article and Full-Text PDF

Role of CCR2 Myeloid Cells in Inflammation Responses Driven by Expression of a Surfactant Protein-C Mutant in the Alveolar Epithelium.

Front Immunol 2021 22;12:665818. Epub 2021 Apr 22.

Pulmonary, Allergy, and Critical Care Division, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.

Acute inflammatory exacerbations (AIE) represent precipitous deteriorations of a number of chronic lung conditions, including pulmonary fibrosis (PF), chronic obstructive pulmonary disease and asthma. AIEs are marked by diffuse and persistent polycellular alveolitis that profoundly accelerate lung function decline and mortality. In particular, excess monocyte mobilization during AIE and their persistence in the lung have been linked to poor disease outcome. Read More

View Article and Full-Text PDF

Feasibility and Outcomes of a Third Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Transplant Cell Ther 2021 May 6;27(5):408.e1-408.e6. Epub 2021 Feb 6.

Hématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, Paris, France.

Few therapeutic options are available for patients with acute myeloid or lymphoblastic leukemia (AML/ALL) relapsing after a second allogeneic stem cell transplantation (alloSCT2). In selected patients a third allogeneic stem cell transplantation (alloSCT3) has been used, but no detailed analysis is available so far. The European Society for Blood and Marrow Transplantation (EBMT) registry was screened for patients with acute leukemia (AL) receiving alloSCT3 from an identical or alternative donor to treat AL in either haematological relapse or disease persistence after alloSCT2 between 2001 and 2018. Read More

View Article and Full-Text PDF

Investigation of water-insoluble hydrophobic polyethylenimines as RNAi vehicles in chronic myeloid leukemia therapy.

J Biomed Mater Res A 2021 May 8. Epub 2021 May 8.

Department of Chemical and Materials Engineering, Faculty of Engineering, University of Alberta, Edmonton, Canada.

The discovery of RNA interference (RNAi) more than two decades ago opened avenues for avant-garde cancer treatments that possess the ability to evade issues hampering current chemotherapeutic strategies, owing to its specific gene sequence-driven mechanism of action. A potent short interfering RNA (siRNA) delivery vehicle designed to overcome physiological barriers is imperative for successful RNAi therapy. For this purpose, this study explored the characteristics and therapeutic efficacy of low-molecular weight (MW) polyethylenimine (PEI) with high cholesterol substitution, yielding water-insoluble polymers, in chronic myeloid leukemia (CML) K562 cells. Read More

View Article and Full-Text PDF

Single-cell Transcriptomics Uncover a Novel Role of Myeloid Cells and T-lymphocytes in the Fibrotic Microenvironment in Peyronie's Disease.

Eur Urol Focus 2021 May 4. Epub 2021 May 4.

Laboratory of Experimental Urology, Department of Development and Regeneration, KU Leuven, Leuven, Belgium; Department of Urology, University Hospitals Leuven, Leuven, Belgium.

Background: Peyronie's disease (PD) is an acquired fibrotic disease affecting the penile tunica albuginea that can lead to curvature and deformities, shortening, and erectile dysfunction. Although immunological mechanisms have been suggested for the pathophysiology of PD, these have not been investigated using single-cell transcriptomics.

Objective: To investigate the immunological signature of plaques from PD patients using immunohistochemistry (IHC) and single-cell RNA sequencing (scRNA-Seq). Read More

View Article and Full-Text PDF